Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

• Results Overview

  Dupilumab significantly improved eczema symptoms compared to placebo, with the strongest improvements seen in higher doses given more frequently. The treatment was generally safe with similar side effects between treatment and placebo groups.

• Study Summary

  Num Participants:

  379

  Study Type:

  Rct

  Control Group:

  Placebo Once A Week

  Efficacy End Points Treatment:

  {'EASI % change': -68}

  Efficacy End Points Control:

  {'EASI % change': -18}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Nasopharyngitis	Low	28.0

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected
  Nasopharyngitis	Low	26.0